Leucovorin
- Generic Name
- Leucovorin
- Brand Names
- EnBrace HR, EnLyte, Lederle Leucovorin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23N7O7
- CAS Number
- 58-05-9
- Unique Ingredient Identifier
- Q573I9DVLP
- Background
Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro...
- Indication
For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in t...
- Associated Conditions
- Advanced Colorectal Cancer, Advanced Esophageal Cancers, Anemia of Pregnancy, Bladder Cancer, Folate and iron deficiency, Folate deficiency, Folic acid antagonist overdose, Iron Deficiency (ID), Macrocytic anemia, Megaloblastic anemia, Pancreatic Metastatic Cancer, Postpartum Anemia, Stage IV Gastric Cancer, Hypochromic anemia, Methotrexate toxicity, Normochromic anemia, Pyrimethamine hematologic toxicity
- Associated Therapies
- -
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
- Conditions
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 176
- Registration Number
- NCT04233866
- Locations
- 🇺🇸
Mount Carmel East Hospital, Columbus, Ohio, United States
🇺🇸Wake Forest Baptist Health - Hematology Oncology - Statesville, Statesville, North Carolina, United States
🇺🇸Neurosurgeons of New Jersey-Ridgewood, Ridgewood, New Jersey, United States
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
- Conditions
- Interventions
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 703
- Registration Number
- NCT04210115
- Locations
- 🇺🇸
Greater Baltimore Medical Center ( Site 0031), Baltimore, Maryland, United States
🇺🇸Allegheny Health Network ( Site 0042), Pittsburgh, Pennsylvania, United States
🇧🇷ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 0088), Ijui, Rio Grande Do Sul, Brazil
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- Conditions
- Interventions
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 94
- Registration Number
- NCT04205968
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Swedish Medical Center-Ballard Campus, Seattle, Washington, United States
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
- Conditions
- Interventions
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Anne Noonan
- Target Recruit Count
- 9
- Registration Number
- NCT04164069
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
- Conditions
- Interventions
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 770
- Registration Number
- NCT04083235
- Locations
- 🇺🇸
Oncology Consultants, Houston, Texas, United States
🇺🇸Miami Cancer Institute, Miami, Florida, United States
🇺🇸University of Oklahoma - Health Sciences Center, Oklahoma City, Oklahoma, United States
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
- Conditions
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 1408
- Registration Number
- NCT04068103
- Locations
- 🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸Kaiser Permanente South Bay, Harbor City, California, United States
🇺🇸Springfield Memorial Hospital, Springfield, Illinois, United States
Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients
- Conditions
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Target Recruit Count
- 70
- Registration Number
- NCT04072198
- Locations
- 🇮🇹
Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy
🇮🇹Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy
🇮🇹AUSL/IRCCS di Reggio Emilia, Reggio Emilia, Italy
Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation
- Conditions
- Interventions
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 120
- Registration Number
- NCT04034173
- Locations
- 🇩🇪
Ludwigs Maximialians University, Munich, Germany
FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC
- Conditions
- Interventions
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 109
- Registration Number
- NCT04034459
- Locations
- 🇩🇪
Klinikum der Universitaet Muenchen, Munich, Germany
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1147
- Registration Number
- NCT04008030
- Locations
- 🇩🇪
Local Institution - 0117, Hamburg, Germany
🇩🇪Local Institution - 0008, Hannover, Germany
🇩🇪Local Institution - 0009, Heidelberg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.